Kornimate/medical-research-clean huggingface dataset:
combination chemotherapy in treating patients with stage ii bladder cancer

Conditions: Bladder Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combination chemotherapy following surgery in treating patients with stage ii bladder cancer.

objectives: i. determine the efficacy of combination chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (mvac) following aggressive transurethral resection of bladder tumors in patients with stage ii transitional cell carcinoma of the bladder without nuclear overexpression of mutant p53. ii. determine the proportion of patients treated with this regimen in whom bladder preservation rather than radical cystectomy is possible. outline: all patients undergo complete or near complete transurethral resection of the bladder tumor at entry or within 6 weeks prior to entry. upon confirmation of staging and histology, patients receive combination chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (mvac) every 21 days for 4 courses. subcutaneous g-csf is given with each course. patients with a complete response after chemotherapy proceed to intravesical therapy or observation; those with a partial response, stable disease, or progression proceed to definitive surgery. projected accrual: 30 patients will be entered over approximately 18 months.

Eligibility criteria:
disease characteristics: invasive transitional cell carcinoma of the bladder that is clinical stage t2-3a n0 m0 by cystoscopy cystoscopy performed at memorial sloan-kettering cancer center (mskcc) no multifocal carcinoma in situ no obstructive uropathy or palpable mass pathologic confirmation of histology and no more than 20% positive expression of nuclear p53, as follows: on study following transurethral resection of the bladder (turb) or at turb performed within 6 weeks of entry as part of initial staging patient characteristics: age: 18 and over performance status: karnofsky 60%-100% hematopoietic: wbc at least 3,500 platelets greater than 150,000 hepatic: bilirubin less than 2.0 mg/dl renal: creatinine less than 1.5 mg/dl or creatinine clearance greater than 60 ml/min per 1.73 square meters cardiovascular: no nyha class iii/iv status other: no concomitant malignancy other than basal cell skin carcinoma negative pregnancy test required of fertile women adequate contraception required of fertile women prior concurrent therapy: no prior systemic chemotherapy no prior bladder irradiation

Keywords: stage ii bladder cancer transitional cell carcinoma of the bladder
to evaluate sperm parameters in men with secondary hypogonadism previously treated with topical testosterone

Conditions: Secondary Hypogonadism

Summary: the study was designed to determine if androxal® would affect sperm parameters (count, concentration, volume) in men with secondary hypogonadism who have been previously treated with topical testosterone.

the study was designed to determine if androxal® would affect sperm parameters (count, concentration, volume) in men with secondary hypogonadism who have been previously treated with topical testosterone. a maximum of twelve subjects per group were randomized to daily treatments of androxal® or topical testosterone (testim®) for six months. the protocol was later amended to include a treatment group who received androxal after a 3 month wash out period.

Eligibility criteria:
inclusion criteria: * healthy adult males between 21 and 60 years of age who have been diagnosed with aihh. * subjects must have been treated with a topical testosterone replacement therapy (typically androgel® or testim®) for at least 6 months at enrollment and for not more than 2 years. exclusion criteria: * a history of idiopathic infertility due to primary hypogonadism, testicular failure, kallmann's syndrome or any other infertility condition. * subjects demonstrating any clinically significant medical condition rendering the subjects infertile or marginally fertile other than aihh. * men with a history of, known, or suspected prostate disease not ruled out by a prostate biopsy, or a prostate specific antigen (psa)\>3.6 or clinical suspicion of current prostate disease. * men with a hematocrit in excess of 50 % or hemoglobin \>17 g/dl

Keywords: adult onset idiopathic hypothalamic hypogonadism (aihh) secondary hypogonadism semen volume sperm count sperm motility
study to compare u0267 against vehicle in subjects with plaque-type psoriasis one of two phase 3 studies

Conditions: Psoriasis

Summary: the purpose of the study is to demonstrate the safety and efficacy of u0267 in subjects with plaque-type psoriasis.


Eligibility criteria:
inclusion criteria: * male or female subjects at least 12 years old and in good general health. * mild to moderate plaque-type psoriasis exclusion criteria: * known allergy or other adverse reaction to calcipotriene or other vitamin d analogs; or to any component of the investigational formulations * history of hypercalcemia or of vitamin d toxicity. * diagnosis of generalized pustular or erythrodermic exfoliative psoriasis. * other serious skin disorder or any chronic medical condition that is not well controlled. * use of non-biologic systemic anti-psoriatic therapy or biologic therapy within four weeks of enrollment. * use of topical therapies that have a known beneficial effect on psoriasis, within 2 weeks of enrollment. * systemic medications for other medical conditions that are known to affect psoriasis within the past four weeks of enrollment. * use of any investigational therapy within 4 weeks of enrollment. * pregnant women, women who are breast feeding, or sexually active women of child bearing potential who are not practicing an acceptable method of birth control.

Keywords: plaque-type psoriasis psoriasis
effects of remifentanil on respiratory function in mechanically ventilated patients

Conditions: Respiratory Insufficiency; Respiration, Artificial; Conscious Sedation

Summary: sedation is widely used in mechanically ventilated patients. propofol, benzodiazepines and opioids are the most used drugs. the study hypothesis is that sedation with remifentanil (an opioid drug) could improved respiratory pattern and effort in mechanically ventilated patients with rapid shallow breathing or high respiratory rate.


Eligibility criteria:
inclusion criteria: * pressure support ventilation or cpap * respiratory rate \> 35.min-1 * respiratory rate/tidal volume \> 105 exclusion criteria: * vasoactive agents (dopamine lower than 5 mcg.kg-1.min-1 is not considered as vasoactive agent) * body temperature \> 38 °c * glasgow coma scale \< 9 * fio2 \> 0.6 * peep \> 10 cmh2o * ph \< 7.30

Keywords: respiratory insufficiency respiration, artificial remifentanil respiratory mechanics work of breathing
hotspot study: implement and evaluate the prep implementation strategy

Conditions: PrEP; HIV; Incarceration

Summary: the goal of this study is to measure the implementation and effectiveness of a multicomponent strategy for prep for people who are incarcerated at the dallas county jail. specifically, based on a patients risk score on an electronic medical record hiv prediction model, referrals from providers and/or patient self-referrals, a prep patient navigator will meet with individuals at the jail to discuss hiv risk, offer hiv/sti testing if not yet completed and offer education around prep with referrals to community-based prep providers.

the objective of aim 3 is to deploy the multicomponent strategy that was refined in aim 2 and evaluate its impact on prep implementation and related clinical outcomes using iterative quantitative and qualitative assessments. the investigators' approach will be to utilize the epis framework (exploration, preparation, implementation, sustainment) across the jail-to-community continuum. the investigators will use mixed-methods to evaluate implementation process measures and an interrupted time series design to measure clinical outcomes for prep evaluations and linkage, as well as hiv/sti testing and diagnoses. the investigators' expected outcome is to define a feasible, acceptable and effective prep implementation strategy for jails.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * incarcerated in dallas county jail exclusion criteria: * severe medical or psychiatric disability making participation unsafe * unable to provide consent * not remaining in the local area after release from custody
a comparison of beverages consumed within a meal to satiation on meal-time food intake and post-meal appetite and glycemic response in healthy young adults

Conditions: Obesity; Hyperglycemia

Summary: the objective of the current study is to determine the effects of an ad libitum intake of 1% milk, fruit juice, regular cola, diet cola and water, as part of a pizza meal, on meal food intake, appetite and postprandial blood glucose in healthy men and women. we hypothesize that 1% milk will reduce food intake and result in better post-meal glycemic response compared to the other beverages.


Eligibility criteria:
inclusion criteria: * healthy men and women * age 20-30 years * bmi between 20-24.9 kg/m\^2 exclusion criteria: * breakfast skippers * diabetes or any metabolic diseases * lactose intolerance or allergies to milk * taking medications
rate of pelvic inflammatory disease at st. michael's hospital

Conditions: Pelvic Inflammatory Disease

Summary: a retrospective review of women who came through the er at smh with a pelvic inflammatory disease (pid) or tubo-ovarian abscess (toa) between 1995-2005. they were looking at people with this diagnosis to determine how they were treated, whether as inpatient or outpatient and whether they were treated with drugs and how were these given and also did they develop an abscess.


Eligibility criteria:
inclusion criteria: * women admitted to emergency with pelvic-inflammatory disease or tubo-ovarian abscess from the year range: 1995-2000 exclusion criteria: -

Keywords: tubo-ovarian abscess, pelvic-inflammatory disease
liraglutide effectiveness in preoperative weight-loss for bariatric-metabolic surgery

Conditions: Weight Loss; Bariatric Surgery Candidate; Obesity, Morbid

Summary: severe obesity is associated with considerable reduction of wellbeing and life expectancy. people living with severe obesity tend to die 8 to 10 years earlier. preoperative management of patients living with severe obesity can be challenging and proper weight-loss may help obtain better outcomes and less morbidity. the effectiveness of glp-1 analogue liraglutide in preoperative weight-loss was evaluated in the study.

objective: determine liraglutide effectiveness for preoperative weight-loss in patients with severe obesity undergoing bariatric-metabolic surgery. methods: it is a single center, quasi-experimental prospective before-and-after study. all patients were assigned the same pharmacological treatment with liraglutide, initiating dosing with 0.6 mg per day escalating 0.6 mg every week up to 3.0 mg. the treatment dose was delivered once daily via subcutaneous injection for 3 months (12 weeks). weight-loss and percentage weight-loss was evaluated monthly using bioelectric impedance (bia) final result at week 12.

Eligibility criteria:
inclusion criteria: * patients with bmi greater than 48 kg/m2 in pre-surgical protocol for bariatric surgery of the bariatric and metabolic surgery unit of the civil hospital of guadalajara "dr. juan i. menchaca exclusion criteria: * patients under 18 years of age or over 65 years of age. * pregnant patients. * patients who do not agree to give their consent and take part in the study. * patients with allergy to liraglutide, multiple endocrine neoplasia type 2 and medullary thyroid cancer, gallstones. removal: * patients who decide to abandon the study. * patients who do not follow the instructions or do not adhere to the treatment.

Keywords: preoperative weight loss
the effect of phonophoresis in subacromial impingement syndrome.

Conditions: Subacromial Impingement Syndrome

Summary: subacromial impingement syndrome (sis) is a dysfunction caused by an impingement of the rotator cuff tendon between the head of the humerus and the acromion as a result of changes in the subacromial space. the patients' symptoms, such as pain, limited joint mobility and reduced strength, may lead to a diagnosis of sis. the conservative treatment of individuals with sis is includes analgesics and non-steroidal anti-inflammatory drugs (nsaids), steroid injections and physiotherapy. ultrasound therapy is one of the common physiotherapy applications for sis, but its effectiveness is controversial. phonophoresis is a combination of ultrasound therapy and medical therapy. in phonophoresis, a medicine in gel form is used as a transmitter with ultrasound instead of the aquatic conductor gel. it was hypothesized that ultrasound waves favoring the penetration of an anti-inflammatory drug would lead to an improved response to the treatment of sis. however, the effectiveness of ultrasound modes (pulsed or continuous) can be used in phonophoresis is debatable. the purpose of this study is to determine the effect of ultrasound therapy, pulsed mode ultrasound and continuous mode ultrasound phonophoresis in patients with sis.


Eligibility criteria:
inclusion criteria: * to be diagnosed as shoulder impingement syndrome, * shoulder pain for at least one month, * vas score over 40mm. exclusion criteria: * grade iii supraspinatus tendon injury, * major shoulder trauma, * diabetes mellitus, * hipotiroidizm, * adhesive capsulitis, * cardiac pacemaker * physical therapy or local injection to the shoulder at last six month * serious cervical pathologies.

Keywords: subacromial pain ultrasound therapy phonophoresis
an open label clinical study to evaluate tanruprubart (also commonly known as anx005) in participants with guillain-barré syndrome (forward study)

Conditions: Guillain-Barre Syndrome

Summary: the goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the united states, canada, and europe.


Eligibility criteria:
key inclusion criteria: * diagnosis of gbs according to the national institute of neurological disorders and stroke diagnostic criteria for gbs. * onset of gbs-related weakness ≤10 days before start of infusion on day 1 * gbs-disability score (ds) score of 3, 4, or 5 at screening and before start of infusion on day 1. key exclusion criteria: * previous or intended treatment with either plasma exchange or iv immunoglobulin for gbs. * diagnosis of a variant of gbs, including miller fisher syndrome, bickerstaff's encephalitis, and overlap syndromes. other protocol-defined criteria may apply.

Keywords: guillain-barre syndrome gbs anx005 tanruprubart forward study
multi-center study of clinical and inflammatory outcomes in intensive cardiac rehabilitation and traditional cardiac rehabilitation programs

Conditions: Cardiovascular Diseases

Summary: the goal of this prospective study is to evaluate whether the intensive cardiac rehabilitation (icr) program provides incremental benefits over the traditional cardiac rehabilitation (tcr) program, defined by readmission costs. the study aims to confirm: * that icr is associated with better outcomes than tcr, defined as lower readmission costs, lower incidence of major adverse cardiovascular events (mace), and improvement in biomarkers, epigenetic markers, and inflammatory markers. * the addition of food to the icr program will further improve these outcomes. icr-eligible participants * will be randomized into one of three groups: (1) icr 72 session program with home-delivered c2life® supplied food, (2) icr 72 session without c2life® supplied food, or (3) tcr 36 session program without c2life supplied food * biometric measurements and laboratory measurements will be performed at entry into the rehab intervention, discharge from rehab intervention, and at 6 months after discharge. * epigenetic measurements will be performed at admission and discharge from the rehab intervention


Eligibility criteria:
inclusion criteria: * all patients eligible for an intensive cardiac rehabilitation (icr) program at each of the three study sites outline below, stratified by one of the following qualifying cardiovascular events, including myocardial infarction (stemi and nstemi), angioplasty and stents, coronary artery bypass, surgical or percutaneous valve repair or replacement, and stable congestive heart failure with reduced ejection fraction of 35% or less. exclusion criteria: * anticipated life expectancy of under 2 years * any co-morbidity that would limit participation in the study.

Keywords: intensive cardiac rehabilitation traditional cardiac rehabilitation
the fetal epicardial thickness in obese pregnant women (eft)

Conditions: Fetus Fetus; Pregnancy Complications

Summary: the effects of fetal eft on fetal cardiac function and fetal and maternal outcomes were investigated in obese pregnant women compared with normal-weight pregnant women.

all pregnant women underwent a comprehensive fetal anomaly screening. one obstetrician (s.d.) assessed all of the measurements. every measurement was performed using a convex 2-5 mhz voluson e8 probe (ge healthcare, milwaukee, wi). fetal biometry, ua, mca doppler, cerebroplacental ratio (cpr), modified mpi (mod-mpi), and eft were assessed in accordance with the international society of ultrasound in obstetrics and gynecology (isuog) guidelines

Eligibility criteria:
inclusion criteria: * obese pregnant women * normal-weight pregnant women * 24-40 gestational week exclusion criteria: twin pregnancies, structural and chromosomal abnormalities, fetal rhesus isoimmunization, fetal growth restriction, cases with infections detected by maternal serological tests, pregestational or gestational diabetes (all patients underwent a 75-gram glucose load test at 24 weeks to rule out diabetes), preeclampsia, premature rupture of membranes were excluded from the study -

Keywords: obesity, fetal epicardial thickness myocardial performance index perinatal outcome
norwegian microemboli in acute stroke study

Conditions: Ischemic Stroke; Embolic Stroke; Microemboli

Summary: background: the cause of ischemic stroke remains undetermined in 30-40% of the cases, but circulating blood clots (thromboemboli) are a postulated common denominator in approx. 75% of patients. transcranial doppler monitoring (tcdm) is a non-invasive method of detecting circulating microemboli (cme) in the human cerebral circulation. the method is not used systematically in unselected groups of patients with repeated long-term registrations. new ultrasound equipment is ambulatory, less unpleasant for the patient and allows extended monitoring sessions. this may vastly simplify the implementation of tcdm as a clinically useful diagnostic tool. aims: determine the usefulness of tcdm in acute stroke diagnostics by assessing prevalence and frequency of cme in unselected patients with ischemic stroke, the influence of antithrombotic drugs on cme and the relationship between mes and recurrent stroke or transient ischemic attack (tia). hypotheses: prevalence and frequency of cme are higher during the first 24 hours than at later follow-up. stroke etiology can be assessed by the presence or absence of cme. presence of cme is associated with increased risk of recurrent tia of stroke within 3 months and 1 year. cessation of cme after the start of antithrombotic treatment is associated with reduced risk of recurrent tia or stroke.

* standardized questionnaire * clinical work-up in accordance with hospital standard operating procedures, i.e. radiological and cardiological procedures, neurovascular ultrasound, clinical scoring, etc. * 1st transcranial doppler monitoring (tcdm) at admission if within 24 hours after stroke onset (day 1). tcdm is repeated at 18-36 hours and at day 3. microembolic signals are automatically registered by the software and subsequently verified manually.

Eligibility criteria:
inclusion criteria: * admitted to hospital \< 24 hours after onset of ischemic stroke exclusion criteria: * temporal bone window inadequate for transcranial doppler examination * participation in ongoing sonothrombolysis study (nor-sass 2) * reduced ability to cooperate * no informed consent can be obtained
clinical outcomes of the endoscopic resection of premalignant and malignant gastrointestinal lesions

Conditions: Gastrointestinal Neoplasms; Benign Neoplasm of Intestinal Tract

Summary: to evaluate clinical outcome for patients receiving treatment of suspected premalignant and malignant gastrointestinal lesions at interventional endoscopy services. the primary outcome is curative endoscopic resection. secondary outcomes include resection technique utilized, rates of en bloc resection and adverse event rates, including infection, bleeding, perforation and death, and one-year survival rates.


Eligibility criteria:
inclusion criteria: * patients age \>18 years that have been referred for endoscopic treatment of gi lesions. exclusion criteria: * patients for whom endoscopic treatment was not performed.
implementation of the npms obstetric hemorrhage bundle at a tertiary center: utilization of the delphi method

Conditions: Pregnancy Hemorrhage; Postpartum Hemorrhage

Summary: the national partnership for maternal safety (npms) developed an obstetric hemorrhage consensus bundle to provide every united states birthing facility consistent, validated practice guidelines. to facilitate implementation of each element of this bundle at the participants large tertiary center, the investigators utilized the delphi method to identify deficiencies, perceived barriers to implementation, and multidisciplinary consensus on changes with high feasibility and impact on patient care.


Eligibility criteria:
inclusion criteria: * ≥ five years of experience on the l\&d unit * current employment on the l\&d unit \> 20h per week * prior involvement in clinical obstetric hemorrhage situations exclusion criteria: * none
effects of 5htp and ldopa on cns excitability after sci

Conditions: Spinal Cord Injuries

Summary: this study will examine whether supplementation with the serotonin and dopamine precursors, 5htp and l-dopa can alter central nervous system excitability and improve motor function after incomplete and complete spinal cord injuries.


Eligibility criteria:
inclusion criteria: * individuals aged 18-65 years of age. * patients must have suffered a trauma to the spinal cord at least 1 year ago or longer. * patients must exhibit some degree of spasticity which can be self-reported (penn spasm frequency) or if assessed by a physiotherapist, a modified ashworth spasticity score greater than 1 exclusion criteria: * individuals with damage to the nervous system other than to the spinal cord * pregnant or breastfeeding women * alcoholic patients * patients with a history of seizures or epilepsy * patients with a history of suicidal thoughts or behaviors * patients with active or inactive implants including cardiac pacemakers, implantable defibrillators, ocular implants, deep brain stimulators, vagus nerve stimulator, and implanted medication pumps * patients with conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head * patients with: * known or suspected allergy to the medication or the ingredients * cardiovascular disease including history of heart attack or heart rhythm irregularities * coronary artery disease * comatose or depressed states due to cns depressants * endocrine dysfunction * blood dyscrasias * bone marrow depression * history of seizures * hypocalcemia * history of stomach ulcers * wide-angle glaucoma * phenylketonuria patients taking: * monoamine oxidase inhibitor therapy * serotonergic antidepressants: selective serotonin and norepinephrine reuptake inhibitors * tricyclic antidepressants * any type of serotonergic agonist * dopamine d2 receptor antagonists * amphetamine * cns depressants * levodopa * lithium * anti-hypertensive drugs (carbidopa and l-dopa) * iron salts * metoclopramide * phenothiazine medication